Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports on breast cancer findings from Centre Hospitalier Lyon Sud provide new insights
October 2nd, 2008
According to a study from Pierre-Benite, France, "This open controlled prospective study aimed at evaluating the medical and economical impact of first line chemotherapy for metastatic breast cancer (MBC). Two groups of HER + + +. MBC patients were compared: 26 were treated by a combination of trastuzumab and paclitaxel in 4 ''prescriber'' centers (group A) and 19 patients were treated by any chemotherapy without addition of trastuzumab, in 6 control centers (group 13)." "The cost of chemotherapy and related hospitalizations was taken into account during the first 8 cycles. Forty-five patients, mean age 51 years have been included. The objective response rate was...
Source: Women's Health Weekly (2008-10-02)
|
